1. Home
  2. LIXT vs ISPC Comparison

LIXT vs ISPC Comparison

Compare LIXT & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • ISPC
  • Stock Information
  • Founded
  • LIXT 2005
  • ISPC 2009
  • Country
  • LIXT United States
  • ISPC United States
  • Employees
  • LIXT N/A
  • ISPC N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • ISPC Precision Instruments
  • Sector
  • LIXT Health Care
  • ISPC Health Care
  • Exchange
  • LIXT Nasdaq
  • ISPC Nasdaq
  • Market Cap
  • LIXT 3.0M
  • ISPC 3.1M
  • IPO Year
  • LIXT N/A
  • ISPC 2021
  • Fundamental
  • Price
  • LIXT $0.74
  • ISPC $0.94
  • Analyst Decision
  • LIXT
  • ISPC
  • Analyst Count
  • LIXT 0
  • ISPC 0
  • Target Price
  • LIXT N/A
  • ISPC N/A
  • AVG Volume (30 Days)
  • LIXT 82.2K
  • ISPC 51.4K
  • Earning Date
  • LIXT 08-07-2025
  • ISPC 08-05-2025
  • Dividend Yield
  • LIXT N/A
  • ISPC N/A
  • EPS Growth
  • LIXT N/A
  • ISPC N/A
  • EPS
  • LIXT N/A
  • ISPC N/A
  • Revenue
  • LIXT N/A
  • ISPC $8,058,631.00
  • Revenue This Year
  • LIXT N/A
  • ISPC $35.93
  • Revenue Next Year
  • LIXT N/A
  • ISPC N/A
  • P/E Ratio
  • LIXT N/A
  • ISPC N/A
  • Revenue Growth
  • LIXT N/A
  • ISPC N/A
  • 52 Week Low
  • LIXT $0.64
  • ISPC $0.86
  • 52 Week High
  • LIXT $3.00
  • ISPC $11.80
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 30.79
  • ISPC 37.62
  • Support Level
  • LIXT $0.64
  • ISPC $0.86
  • Resistance Level
  • LIXT $0.93
  • ISPC $0.97
  • Average True Range (ATR)
  • LIXT 0.13
  • ISPC 0.06
  • MACD
  • LIXT -0.05
  • ISPC -0.02
  • Stochastic Oscillator
  • LIXT 16.99
  • ISPC 18.79

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About ISPC iSpecimen Inc.

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

Share on Social Networks: